These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 25538217)

  • 1. Granulocytic sarcoma in a patient with chronic myeloid leukaemia in complete haematological, cytogenetic and molecular remission.
    Kittai A; Yu EM; Tabbara I
    BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25538217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple skin chloromas: a rare presentation of chronic myelogenous leukaemia in chronic stable phase.
    Kumar V; Jain N; Chaudhary SC; Mishra S
    BMJ Case Rep; 2013 Apr; 2013():. PubMed ID: 23592814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
    Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
    Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ph-negative isolated myeloid sarcoma with NPM1 gene mutation in adolescent with Ph-positive chronic myeloid leukemia in remission after treatment with allogeneic bone marrow transplantation and imatinib mesylate.
    Skalska-Sadowska J; Januszkiewicz-Lewandowska D; Derwich K; Pieczonka A; Samborska M; Wachowiak J
    Pediatr Blood Cancer; 2015 Jun; 62(6):1070-1. PubMed ID: 25631405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.
    Ahmed MS; Kroft SH; Davis NB; King DM; Cheng YC
    Leuk Res; 2008 Sep; 32(9):1476-9. PubMed ID: 18308388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Imatinib therapy in chronic myeloid leukemia].
    Egyed M; Kollár B; Rajnics P; Karádi E; Matolcsi A
    Orv Hetil; 2008 Aug; 149(32):1509-12. PubMed ID: 18672441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.
    Poláková KM; Polívková V; Rulcová J; Klamová H; Jurcek T; Dvoráková D; Zácková D; Pospísil Z; Mayer J; Moravcová J
    Exp Hematol; 2010 Jan; 38(1):20-6. PubMed ID: 19837125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Imatinib mesylate in treatment of childhood chronic myeloid leukaemia. Preliminary report].
    Pogorzała M; Styczyński J; Jankowska K; Kurylak A; Wysocki M
    Med Wieku Rozwoj; 2006; 10(3 Pt 1):603-12. PubMed ID: 17317891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia.
    Ghanima W; Kahrs J; Dahl TG; Tjonnfjord GE
    Eur J Haematol; 2004 Jun; 72(6):441-3. PubMed ID: 15128424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
    Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
    Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year follow-up of patients treated with imatinib mesylate for chronic myeloid leukaemia in Trinidad and Tobago.
    Charles KS; Ramon L; Leelah N; Oluwabusi TA; Seemungal T
    West Indian Med J; 2011 Jun; 60(3):298-302. PubMed ID: 22224342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraoral granulocytic sarcoma presenting as multiple maxillary and mandibular masses: a case report and literature review.
    Xie Z; Zhang F; Song E; Ge W; Zhu F; Hu J
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jun; 103(6):e44-8. PubMed ID: 17428693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy.
    Rosário Cavalheiro Rde C; Vicari P; Maria Morselli F; Ommati LV; Frazão Rosa Fde O; Rodrigues Oliveira JS
    Am J Hematol; 2006 Jan; 81(1):76-7. PubMed ID: 16369975
    [No Abstract]   [Full Text] [Related]  

  • 16. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
    Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
    Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
    Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of Ph negative acute myeloid leukemia in a patient with minor-BCR/ABL positive chronic myeloid leukemia achieving a partial cytogenetic response during tyrosine kinase inhibitor treatment].
    Fujii S; Miura I; Tanaka H
    Rinsho Ketsueki; 2015 Jun; 56(6):681-6. PubMed ID: 26256879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful use of National Cancer Registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia.
    Shepherd P; Dhanapala C; Maguire C; White J; Drummond M; Holyoake T; Johnson PR
    Scott Med J; 2008 Aug; 53(3):8-12. PubMed ID: 18780518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.